Market Access

Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul

by
Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul

Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) … Read more

TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats

by
TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats

Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.

CMS’ Medicaid drug payment model brings Trump’s MFN push

by
CMS' Medicaid drug payment model brings Trump's MFN push

CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, … Read more

Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns

by
Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns

The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.